2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025)
San Francisco, California, US 23 January 2025 - 25 January 2025
Real-world data support FTD/TPI plus bevacizumab for mCRC
A combination regimen comprising trifluridine/tipiracil (FTD/TPI) and bevacizumab demonstrates favourable efficacy and safety in individuals with metastatic colorectal cancer (mCRC) in the real-world BeTAS study presented at ASCO GI 2025.
Real-world data support FTD/TPI plus bevacizumab for mCRC
03 Mar 2025
Low-dose aspirin halves recurrence risk in select CRC patients
In colorectal cancer (CRC) patients harbouring mutations in the PI3K pathway, adjuvant treatment with aspirin 160 mg daily reduced the recurrence rate by over 50 percent, according to the 3-year results from the ALASCCA trial.
Low-dose aspirin halves recurrence risk in select CRC patients
28 Feb 2025
First-line nivolumab-ipilimumab therapy extends survival in unresected HCC
Treatment with nivolumab plus ipilimumab in the frontline setting provides clinically meaningful overall survival (OS) benefit compared with lenvatinib or sorafenib to patients with unresectable hepatocellular carcinoma (HCC) who were naive to systemic therapy, according to data from the phase III CheckMate 9DW study presented at ASCO GI 2025.
First-line nivolumab-ipilimumab therapy extends survival in unresected HCC
25 Feb 2025
Aspirin use lowers risk of common GI cancers
Taking aspirin contributes to a reduced risk of several gastrointestinal (GI) malignancies, such as colorectal cancer (CRC), liver cancer, stomach cancer, and pancreatic cancer, as shown by the results of a 20-year study presented at ASCO GI 2025. However, no association is seen with most non-GI cancers.
